Court skeptical of bid to cut abortion pill access
The panel questioned whether Louisiana can revive a challenge that the Supreme Court already paused while the FDA reviews mifepristone safety.
- On Wednesday, Louisiana Attorney General Liz Murrill appeared before a federal appellate court challenging FDA policies that allow abortion medication prescriptions via telehealth and mail dispensing.
- Murrill's case, part of a five-state legal effort, targets a 2023 FDA revision removing in-person requirements for mifepristone; plaintiffs cite the Comstock Act, a 19th-century law prohibiting the mailing of obscene materials.
- Appellate judges appeared skeptical during Wednesday's hearing, questioning Louisiana Solicitor General Benjamin Aguiaga's request to repeat actions the Supreme Court has already stymied.
- Murrill signaled Wednesday she hopes the Trump administration will unilaterally eliminate the telehealth policy, citing President Donald Trump's nominee for FDA administrator, Dr. Heidi Overton, as a potential catalyst.
- The FDA conducts a safety review due on October 7, while the administration has maintained existing mifepristone access despite pressure from anti-abortion groups.
15 Articles
15 Articles
Fifth Circuit Judges Seem Skeptical of Louisiana’s Challenge to Telehealth Abortion
On Wednesday, Sep. 9, a three-judge panel of the 5th Circuit Court of Appeals in New Orleans heard oral arguments in Louisiana v. FDA, a lawsuit filed by the Louisiana attorney general seeking to end telehealth abortion nationwide, even in states that protect abortion access. Since the fall of Roe and a national snapback of abortion rights in a majority of U.S. states, the antiabortion movement has been laser focused on trying to restrict telehe…
Louisiana presses abortion-pill challenge before Fifth Circuit
(The Center Square) — A federal appeals court on Wednesday pressed Louisiana on whether it can legally blame the Food and Drug Administration for abortion pills being mailed into the state, as Louisiana sought to restore an in-person dispensing requirement for mifepristone nationwide. During oral arguments before the U.S. Fifth Circuit Court of Appeals in […] The post Louisiana presses abortion-pill challenge before Fifth Circuit appeared first …
Appeals against mifepristone have repeatedly encountered obstacles in the Supreme Court on grounds of legitimacy, and the appellate court, which twice ruled that the easing of the statute of limitations violated the statutory procedure, is wary of the possibility of revoking its judgement.
Omaha World-Herald
Court skeptical of bid to cut abortion pill access
A U.S. appeals court on Wednesday appeared skeptical of a bid by the Republican-led state of Louisiana to curtail access to the abortion drug mifepristone by blocking a 2023 rule that allowed the medication to be prescribed via telemedicine and…
Coverage Details
Bias Distribution
- 50% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
